F-1: Evaxion Biotech Seeks to Resell 19.4 Million Ordinary Shares via American Depositary Shares

Evaxion Biotech is registering for resale up to 19,453,796 ordinary shares represented by 1,945,379 American Depositary Shares (ADSs) by selling shareholders.

Summary

• Evaxion Biotech has filed a registration statement for the resale of up to 19,453,796 ordinary shares, represented by 1,945,379 American Depositary Shares (ADSs), by its selling shareholders.
• These shares were previously issued to the selling shareholders through a private placement that closed on December 21, 2023.
• The private placement included the issuance of 9,726,898 ordinary shares represented by ADSs and warrants to purchase an additional 9,726,898 ordinary shares represented by ADSs.
• The warrants have an exercise price of $0.707 per ordinary share and expire three years after the closing date of the private placement.
• Evaxion Biotech will not receive any proceeds from the resale of these ADSs by the selling shareholders, unless the warrants are exercised, in which case they may receive up to $6,876,917.
• The company intends to use any proceeds from warrant exercises to advance its preclinical and clinical pipeline, and for continuing operating expenses and working capital.
• The ADSs are listed on The Nasdaq Capital Market under the symbol EVAX.
• As of April 18, 2024, Evaxion Biotech had 54,110,546 ordinary shares outstanding.
• The company is considered an emerging growth company and a foreign private issuer, which allows for reduced public company reporting requirements.

Sentiment

Score: 6

Explanation: The document is primarily factual, outlining the details of a share resale and previous capital raising activities. The sentiment is neutral, with a mix of potential positives (advancing pipeline) and risks (dependence on financing).

Positives

• Potential influx of up to $6.8 million if warrants are exercised, which will be used to advance the pipeline and for working capital.
• The company is an emerging growth company, allowing for reduced reporting requirements.
• The company has a clinical-stage oncology pipeline of novel personalized therapeutic vaccines and a pre-clinical prophylactic vaccine pipeline for bacterial and viral diseases with high unmet medical needs based on AI-Immunology identified vaccine targets.

Negatives

• The company will not receive any proceeds from the sale of ADSs by the selling shareholders unless the warrants are exercised.
• The company has incurred significant losses since its inception, and anticipates that it will continue to incur significant losses for the foreseeable future.
• The company will require substantial additional financing to achieve its goals, and a failure to obtain this capital on acceptable terms, or at all, could force us to delay, limit, scale back or cease our product development activities or any other or all operations.

Risks

• The company is a clinical-stage TechBio company with product candidates currently in clinical development.
• The company has a limited operating history and no vaccine has been approved using its technology.
• The company is dependent upon successfully concluding partnerships to advance its product candidates to monetize its assets.
• The company will require substantial additional financing to achieve its goals, and a failure to obtain this capital on acceptable terms, or at all, could force us to delay, limit, scale back or cease our product development activities or any other or all operations.
• The sale of a substantial amount of our ordinary shares represented by ADSs, including resale of the ordinary shares represented by ADSs issuable upon the exercise of the warrants held by the selling shareholders in the public market could adversely affect the prevailing market price of our ordinary shares.

Future Outlook

The company intends to use any proceeds from warrant exercises to advance its preclinical and clinical pipeline, and for continuing operating expenses and working capital.

Industry Context

Evaxion Biotech operates in the competitive biotechnology and pharmaceutical industries, focusing on AI-driven immunology for vaccine development.

Comparison to Industry Standards

• The document does not contain specific comparisons to industry standards.
• The document does not contain specific comparible companies, projects, and results.

Management Changes

Stakeholder Impact

• Shareholders may experience dilution if warrants are exercised and new shares are issued.
• The resale of shares by selling shareholders could affect the market price of the ADSs.
• The company's ability to advance its pipeline and operations depends on securing additional funding.

Next Steps

• The selling shareholders may offer the shares for resale from time to time.
• The company will use any proceeds from warrant exercises to advance its preclinical and clinical pipeline, and for continuing operating expenses and working capital.

Key Dates

Keywords

ADS, ordinary shares, warrants, private placement, resale, Evaxion Biotech, registration statement, selling shareholders